These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 26464193)

  • 1. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
    Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression in papillary renal cell carcinoma.
    Motoshima T; Komohara Y; Ma C; Dewi AK; Noguchi H; Yamada S; Nakayama T; Kitada S; Kawano Y; Takahashi W; Sugimoto M; Takeya M; Fujimoto N; Oda Y; Eto M
    BMC Urol; 2017 Jan; 17(1):8. PubMed ID: 28086852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
    Lee KS; Yun S; Lee K; Moon S; Choe G
    Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
    Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
    Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
    Erlmeier F; Weichert W; Autenrieth M; Wiedemann M; Schrader AJ; Hartmann A; Ivanyi P; Steffens S
    Med Oncol; 2017 May; 34(5):71. PubMed ID: 28353093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
    Callea M; Albiges L; Gupta M; Cheng SC; Genega EM; Fay AP; Song J; Carvo I; Bhatt RS; Atkins MB; Hodi FS; Choueiri TK; McDermott DF; Freeman GJ; Signoretti S
    Cancer Immunol Res; 2015 Oct; 3(10):1158-64. PubMed ID: 26014095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
    Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
    Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
    Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
    Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
    Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
    Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
    Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
    Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
    Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
    Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
    Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
    Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.